Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
95 hedge funds and large institutions have $423M invested in Apellis Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 33 increasing their positions, 25 reducing their positions, and 11 closing their positions.
145% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 11
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
32% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 25
20% more funds holding
Funds holding: 79 → 95 (+16)
4.2% more ownership
Funds ownership: 52.88% → 57.09% (+4.2%)
20% less capital invested
Capital invested by funds: $528M → $423M (-$105M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
+$27.5M |
| 2 |
BlackRock
New York
|
+$13.5M |
| 3 |
FT
Fiduciary Trust
Boston,
Massachusetts
|
+$10.8M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$5.06M |
| 5 |
O
OrbiMed
New York
|
+$5.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$34.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$16M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$7.67M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$7.36M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.59M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DTL
101
Dynamic Technology Lab
Singapore
| – | -$447K | -25,164 | Closed |
|
|
ARTA
102
A.R.T. Advisors
New York
| – | -$416K | -23,446 | Closed |
|
|
BCM
103
BlueCrest Capital Management
St Helier,
Jersey
| – | -$224K | -12,600 | Closed |
|
|
QT
104
Quantbot Technologies
New York
| – | -$111K | -6,269 | Closed |
|
|
TRCT
105
Tower Research Capital (TRC)
New York
| – | -$48K | -2,704 | Closed |
|
106
Pacer Advisors
Malvern,
Pennsylvania
| – | -$46K | -2,602 | Closed |
|
APLS Hedge Fund Activity: Q4 2018 in Review
95 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2018, worth a combined $423M — down 20% from $528M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new APLS positions and 11 closed out — a net gain of 16 holders — while 33 added to existing stakes and 25 trimmed.
The largest buyer was venBio Partners, opening a new position worth an estimated $27.5M. The largest seller was Hillhouse Investment Management, cutting an estimated $34.2M.
- 95 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2018, up from 79 in Q3 2018.
- Funds reported $423M of Apellis Pharmaceuticals stock for Q4 2018, down 20% quarter-over-quarter.
- 27 funds opened new Apellis Pharmaceuticals positions in Q4 2018 and 11 closed out, a net change of +16 holders.
- The largest Apellis Pharmaceuticals buyer in Q4 2018 was venBio Partners, an estimated $27.5M added.
- The largest Apellis Pharmaceuticals seller in Q4 2018 was Hillhouse Investment Management, an estimated $34.2M sold.
Based on aggregated 13F filings for Q4 2018.